The earnings call highlighted strong growth in flowcell sales, improved gross margin, and significant reductions in operating expenses. However, the decline in total revenue and the net decrease in the installed base of systems were notable challenges. The overall sentiment is cautiously optimistic, with positive strategic advancements in software and consumables growth and new CPT codes that could support future reimbursement.

Company Guidance

During the Bionano Second Quarter 2025 Earnings Conference Call, the company reported a total revenue of $6.7 million, reflecting a 13% decrease compared to the same period in 2024, primarily due to the discontinuation of certain services. However, upon adjusting for these discontinued services, the revenue decrease was 5% year-over-year. The company sold 7,233 flowcells, marking a 17% increase from the previous year, and achieved a non-GAAP gross margin of 52%, up from 35% a year ago. Non-GAAP operating expenses dropped by 53% year-over-year to $8.8 million, and the installed base of optical genome mapping systems experienced a net decrease to 378 systems. The company ended the quarter with $27.4 million in cash, cash equivalents, and available-for-sale securities. Bionano reiterated its full-year revenue guidance of $26 million to $30 million and increased its 2025 OGM installation expectations to a range of 20 to 25 new systems. The company is focusing on driving utilization among routine users, with consumables and software revenue rising to 73% of the total product mix in Q2 2025.

Increase in Flowcell Sales

Flowcell sales increased by 17% year-over-year, indicating strong demand and utilization among routine-use customers.

Improved Gross Margin

Non-GAAP gross margin increased significantly to 52% from 35% a year ago, showcasing improvements in product manufacturing costs and cost reduction efforts.

Reduction in Operating Expenses

Non-GAAP operating expenses were reduced by 53% year-over-year from $18.8 million to $8.8 million, reflecting cost efficiency measures.

Strong Software and Consumables Growth

Revenue from consumables and software grew 16% year-over-year in Q2 2025 and 8% for the first half of 2025, indicating increased utilization and customer retention.

New CPT Code for Optical Genome Mapping

A second Category I CPT code from the American Medical Association was established for OGM in evaluating constitutional genetic disorders, which could facilitate reimbursement.

BioNano Genomics (BNGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BNGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-1.91 / -	-31.2	―	―	―
Aug 14, 2025	2025 (Q2)	-2.66 / -1.99	-14.4	86.18% (+12.41)	―
May 14, 2025	2025 (Q1)	- / -	-36	―	―
Mar 31, 2025	2024 (Q4)	-3.02 / -1.15	-36	96.81% (+34.85)	―
Nov 13, 2024	2024 (Q3)	-11.85 / -31.20	-193.2	83.85% (+162.00)	―
Aug 07, 2024	2024 (Q2)	-24.92 / -14.40	-74.4	80.65% (+60.00)	―
May 08, 2024	2024 (Q1)	-38.65 / -36.00	-72	50.00% (+36.00)	―
Mar 05, 2024	2023 (Q4)	-52.24 / -66.90	-78	14.23% (+11.10)	―
Nov 08, 2023	2023 (Q3)	-58.18 / -193.20	-66	-192.73% (-127.20)	―
Aug 09, 2023	2023 (Q2)	-62.55 / -74.40	-66	-12.73% (-8.40)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BNGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$3.21	$3.04	-5.30%
May 14, 2025	$3.74	$3.93	+5.08%
Mar 31, 2025	$2.79	$3.10	+11.11%
Nov 13, 2024	$16.61	$15.35	-7.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioNano Genomics Inc (BNGO) report earnings?

BioNano Genomics Inc (BNGO) is schdueled to report earning on Nov 13, 2025, After Close (Confirmed).

What is BioNano Genomics Inc (BNGO) earnings time?

BioNano Genomics Inc (BNGO) earnings time is at Nov 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BNGO EPS forecast?

BNGO EPS forecast for the fiscal quarter 2025 (Q3) is -1.91.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing